Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px
Document › Details

VTU Technology GmbH. (5/20/15). "Press Release: VTU Technology and Biomay Have Signed License Agreement. Biomay to Apply VTU Pichia Strains for the Production of Recombinant Allergens". Grambach & Vienna.

Organisations Organisation VTU Technology GmbH
  Today Validogen GmbH
  Group KonValue (Group)
  Organisation 2 Biomay AG
Products Product Pichia yeast expression system
  Product 2 antiallergic
Index term Index term Biomay–VTU: recombinant protein production, 201505– license to Pichia pastoris protein expression technology to produce rec allergens
Persons Person Purkarthofer, Thomas (VTU Technology 201412 Head Business Development)
  Person 2 Huber, Hans (Biomay 201505 COO)
     


VTU Technology and Biomay, two leading Austrian biotech companies, announced today, that they have entered into a licensing agreement for the production of recombinant allergens.

VTU Technology, currently offering a very broad and comprehensive Pichia pastoris expression platform, grants Biomay access to VTU´s Pichia pastoris protein expression technology. Biomay, a global leader in allergy immunotherapy, will apply industrial Pichia expression strains generated by VTU for the commercial production of recombinant allergens. Under the terms of the agreement, VTU Technology will receive royalties based on Biomay´s worldwide sales of the recombinant allergens.

VTU´s Pichia platform - standing out due to its diversity of expression tools and ingenious expression strategies - enables the production of high-performance expression strains, high-quality proteins and economically, viable protein production processes. “VTU´s Pichia platform has already been utilized for the production of a wide range of different recombinant proteins with licenses granted to companies from diverse industries. We are very happy to extend this list of partnerships to the allergen space by our agreement with Biomay”, said Thomas Purkarthofer, Head of Business Development at VTU Technology.

“For Biomay, this technology cooperation with VTU is an excellent option for manufacturing of allergens being difficult to express,” adds Hans Huber, Chief Operating Officer at Biomay. “Thereby, we recently managed to produce and offer for sale the major allergen from ragweed pollen, Amb a 1, as a recombinant product.”


About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production. VTU develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins.

Headquartered in Grambach/Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma & life science. The VTU group currently counts around 370 highly qualified employees with subsidiaries in different European countries. The VTU group was able to boost its turnover from 40 million Euro to more than 60 million Euro within last year. More information: www.vtu-technology.com, www.vtu.com


About Biomay

Based in Vienna, Austria, Biomay was the first company worldwide to produce a broad spectrum of major recombinant allergens for research and diagnostic. Today, Biomay puts its strategic focus on specific immunotherapy of allergic diseases. Biomay’s lead product is BM32 – a recombinant-based therapeutic vaccine against grass pollen allergy, which is the most advanced candidate developed from Biomay´s proprietary peptide-carrier technology. BM32 has achieved promising results in a recently concluded Phase IIb placebo-controlled, multinational trial. Additionally, Biomay operates as a Contract Manufacturing Organisation (CMO), offering services for GMP-conform microbial-derived recombinant proteins and plasmid DNA. More information: www.biomay.com


Contact VTU Technology

Thomas Purkarthofer, PhD
Head of Business Development
Parkring 18
A-8074 Grambach
Tel: +43-316-4009-4017
Email: thomas.purkarthofer@vtu.com


Contact Biomay

Hans Huber, PhD
Chief Operating Officer
Lazarettgasse 19
A-1090 Wien
Tel: +43-1-7966296-100
E-mail: info@biomay.com

   
Record changed: 2017-04-02

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px

More documents for KonValue (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px




» top